Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
289893-25-0
Molecular formula
C14H20ClN3O3
Molecular weight
313.78 g/mol
Drug class
Small-molecule therapy for Niemann-Pick disease type Cmechanism-based pharmacological class not established
Mechanism of action
The mechanism(s) by which arimoclomol exerts its clinical effects in patients with Niemann-Pick disease type C is unknown, according to the US prescribing information. Proposed heat-shock-protein/lysosomal effects should not be presented as established clinical mechanism.
Indications / reported uses
In combination with miglustat for treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients aged 2 years and older under the US FDA Miplyffa indication
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Arimoclomol Environmental Risk Assessment (ERA) (the Arimoclomol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.